Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06676449 | TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC | recruiting | Phase 3 | 432 | Fudan UniversityOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07189455 | Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 420 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07303023 | Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC(INCIPT-NPC) | recruiting | Phase 3 | 462 | Fudan UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 300 | Polaris GroupINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT03567889 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients(NeoDREAM) | recruiting | Phase 3 | 186 | Philogen S.p.A.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT04722978 | Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 228 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06908993 | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated(COMET) | recruiting | Phase 3 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07029269 | Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer | recruiting | Phase 3 | 454 | Zuoyi JiaoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07285850 | The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD(ABATE-MASLD) | recruiting | Phase 2 / Phase 3 | 20 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07182682 | A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery | recruiting | Phase 3 | 360 | Dizal (Jiangsu) Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06794775 | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma(SWE-NEO) | recruiting | Phase 3 | 128 | Hildur HelgadottirOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT07188584 | Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer | recruiting | Phase 3 | 166 | Ming-Yuan ChenOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06520163 | Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | recruiting | Phase 3 | 262 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04681417 | Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome(RETINO 2018) | recruiting | Phase 2 / Phase 3 | 225 | Institut CurieOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05381597 | 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer | recruiting | Phase 2 / Phase 3 | 200 | Boston UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07084662 | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma | recruiting | Phase 2 / Phase 3 | 80 | Sun Yat-sen UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia | recruiting | Phase 3 | 486 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Nov 25, 2025 | clinicaltrials |
| NCT06647862 | IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) | recruiting | Phase 3 | 170 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07154069 | Adaptive Immunotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 802 | Sun Yat-sen UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06378138 | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) | recruiting | Phase 2 / Phase 3 | 226 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07232134 | The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia(AML-DS-2025) | recruiting | Phase 3 | 100 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04980716 | Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 524 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07170995 | Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 3 | 460 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07178795 | A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC | recruiting | Phase 3 | 440 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06144164 | A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | recruiting | Phase 3 | 285 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT07103668 | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | recruiting | Phase 3 | 150 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases(ECLIPSE) | recruiting | Phase 3 | 412 | Rakuten Medical, Inc.INDUSTRY | 3 | Oct 15, 2025 | clinicaltrials |
| NCT02000089 | The Cancer of the Pancreas Screening-5 CAPS5)Study(CAPS5) | recruiting | Phase 3 | 9,000 | Johns Hopkins UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT06817161 | Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:(ESTANVO) | recruiting | Phase 3 | 116 | Centre Francois BaclesseOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07203352 | Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL | recruiting | Phase 3 | 154 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 7, 2026source: clinicaltrials